Top

Published in:

01-05-2010

The role of ethnicity, age and gender in venous thromboembolism

Authors: Martina Montagnana, Emmanuel J. Favaloro, Massimo Franchini, Gian Cesare Guidi, Giuseppe Lippi

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2010

Abstract

Venous thromboembolism, including both deep venous thrombosis and pulmonary embolism, is the leading cause of preventable in-hospital mortality. In the inexorable progress towards individualization of risk and personalized medicine, several congenital and acquired risk factors have been identified. However, the influence of some demographical variables, especially ethnicity, age and gender, has largely been under appreciated. Although the incidence of venous thromboembolism varies widely among diverse racial/ethnic cohorts, it appears globally highest in Blacks, is intermediate in Caucasians and is lowest in Asians. The incidence and prevalence of venous thromboembolism is also strongly age-related, increasing nearly 90 fold from <15 to >80 years old. Definitive data on the relative frequency of venous thromboembolism across genders is lacking. Some studies report that gender is not an independent risk factor of venous thromboembolism, while others conclude that female gender might be a protective variable. The purpose of this review is to assess the relationship between such demographic variables and venous thromboembolism.

Ageno W, Squizzato A, Garcia D, Imberti D (2006) Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 32:651–658. doi:10.1055/s-2006-951293 PubMedCrossRef

Lippi G, Franchini M (2008) Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 34:747–761. doi:10.1055/s-0029-1145257 PubMedCrossRef

Lippi G, Franchini M, Montagnana M, Guidi GC (2007) Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework. Semin Thromb Hemost 33:759–770. doi:10.1055/s-2007-1000366 PubMedCrossRef

Bonner L, Coker E, Wood L (2008) Preventing venous thromboembolism through risk assessment approaches. Br J Nurs 17:778–782PubMed

Heit JA (2006) The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 21:23–29. doi:10.1007/s11239-006-5572-y PubMedCrossRef

White RH (2003) The epidemiology of venous thromboembolism. Circulation 107(23 Suppl 1):I4–I8. doi:10.1161/01.CIR.0000078468.11849.66 PubMed

Itakura H (2005) Racial disparities in risk factors for thrombosis. Curr Opin Hematol 12:364–369. doi:10.1097/01.moh.0000167746.26145.53 PubMedCrossRef

Klatsky AL, Baer D (2004) What protects Asians from venous thromboembolism? Am J Med 116:493–495. doi:10.1016/j.amjmed.2004.01.005 PubMedCrossRef

White RH, Zhou H, Romano PS (1998) Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 128:737–740PubMed

10.

White RH, Zhou H, Murin S, Harvey DE (2005) Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93:298–305PubMed

11.

Keenan CR, White RH (2007) The effects of race/ethnicity and sex on the risk of venous thromboembolism. Curr Opin Pulm Med 13:377–383PubMed

12.

Lippi G, Franchini M, Favaloro EJ (2009) Pharmacogenetics of vitamin K antagonists: useful or hype? Clin Chem Lab Med (in press)

13.

Cheuk BL, Cheung GC, Cheng SW (2004) Epidemiology of venous thromboembolism in a Chinese population. Br J Surg 91:424–428. doi:10.1002/bjs.4454 PubMedCrossRef

14.

Kishimoto M, Lim HY, Tokuda Y et al (2005) Prevalence of venous thromboembolism at a teaching hospital in Okinawa, Japan. Thromb Haemost 93:876–879PubMed

15.

Dhillon KS, Askander A, Doraisamy S (1996) Postoperative deep-vein thrombosis in Asian patients is not a rarity. J Bone Joint Surg Br 78:427–430PubMed

16.

Mok CK, Hoaglund FT, Rogoff SM et al (1979) The incidence of deep vein thrombosis in Hong Kong Chinese after hip surgery for fracture of the proximal femur. Br J Surg 66:640–642. doi:10.1002/bjs.1800660914 PubMedCrossRef

17.

Jun ZJ, Ping T, Lei Y, Li L, Ming SY, Jing W (2006) Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. Clin Lab Haematol 28:111–116. doi:10.1111/j.1365-2257.2006.00757.x PubMedCrossRef

18.

Fujimura H, Kambayash J, Monden M et al (1995) Coagulation factor V Leiden mutation may have a racial background. Thromb Haemost 74:1381–1382PubMed

19.

Shen MC, Lin JS, Tsay W (1997) High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb Res 87:377–385. doi:10.1016/S0049-3848(97)00141-2 PubMedCrossRef

20.

Angchaisuksiri P, Atichartakarn V, Aryurachai K, Archararit N, Rachakom B, Atamasirikul K, Tiraganjana A (2007) Risk factors of venous thromboembolism in thai patients. Int J Hematol 86:397–402. doi:10.1007/BF02983995 PubMedCrossRef

21.

Kim TM, Kim JS, Han SW, et al. (2008) Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea. Thromb Res 123:436–443PubMedCrossRef

22.

Bertina RM, Koeleman BP, Koster T et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67. doi:10.1038/369064a0 PubMedCrossRef

23.

Biswas A, Bajaj J, Ranjan R et al (2008) Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis? Clin Chim Acta 392:21–24. doi:10.1016/j.cca.2008.02.018 PubMedCrossRef

24.

Chuansumrit A, Jarutwachirakul W, Sasanakul W, Rurgkhum S, Kadegasem P, Kitpoka P, Sirachainan N (2004) Absence of factor V arg306–thr and low factor V arg306->gly mutation prevalence in Thai blood donors. Southeast Asian J Trop Med Public Health 35:450–452PubMed

25.

Tanaka K, Davie EW, Ikeda Y, Iwanaga S, Saito H, Sueishi K (2008) Clinical role of protein S deficiency in Asian population. In: Tanaka K, Davie EW (eds) Recent advances in thrombosis and hemostasis. Springer, USA, pp 597–613CrossRef

26.

Shen MC, Lin JS, Tsay W (2000) Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. Thromb Res 99:447–452. doi:10.1016/S0049-3848(00)00265-6 PubMedCrossRef

27.

Akkawat B, Rojnuckarin P (2005) Protein S deficiency is common in a healthy Thai population. J Med Assoc Thai 88(Suppl 4):S249–S254PubMed

28.

Ko L, Hsu LA, Hsu TS et al (2006) Functional polymorphisms of FGA, encoding alpha fibrinogen, are associated with susceptibility to venous thromboembolism in a Taiwanese population. Hum Genet 119:84–91. doi:10.1007/s00439-005-0102-0 PubMedCrossRef

29.

Kimura R, Honda S, Kawasaki T et al (2006) Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood 107:1737–1738. doi:10.1182/blood-2005-09-3892 PubMedCrossRef

30.

Kinoshita S, Iida H, Inoue S et al (2005) Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem 38:908–915. doi:10.1016/j.clinbiochem.2005.05.006 PubMedCrossRef

31.

Miyata T, Sato Y, Ishikawa J, et al. (2008) Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res 124:14–18PubMedCrossRef

32.

Mokdad AH, Ford ES, Bowman BA et al (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76–79. doi:10.1001/jama.289.1.76 PubMedCrossRef

33.

Mok CC, Tang SS, To CH, Petri M (2005) Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 52:2774–2782. doi:10.1002/art.21224 PubMedCrossRef

34.

Uthman I, Khamashta M (2005) Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis 64:1671–1676. doi:10.1136/ard.2005.038448 PubMedCrossRef

35.

Ferdinand KC (2008) Cardiovascular disease in blacks: can we stop the clock? J Clin Hypertens (Greenwich) 10:382–389. doi:10.1111/j.1751-7176.2008.07918.x CrossRef

36.

Patel RK, Ford E, Thumpston J et al (2003) Risk factors for venous thrombosis in the black population. The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study. Thromb Haemost 90:835–888PubMed

37.

Miller CH, Dilley A, Richardson L et al (2001) Population differences in von Willebrand factor levels affect the diagnosis of von Willebrands disease in African-American women. Am J Hematol 67:125–129. doi:10.1002/ajh.1090 PubMedCrossRef

38.

O’Donnell J, Laffan MA (2001) The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 11:343–351. doi:10.1046/j.1365-3148.2001.00315.x PubMedCrossRef

39.

Cox Gill JC, Endres-Brooks J, Bauer PJ et al (1987) The effect of ABO blood group in the diagnosis of von Willebrand disease. Blood 69:1691–1695

40.

Mwangi J (1999) Blood group distribution in an urban population of patient targeted blood donors. East Afr Med J 76:615–618PubMed

41.

James A (2003) Allelic frequencies of thrombophilic polymorphisms among African-Americans. J Thromb Haemost 1(suppl):P0946

42.

Rasmussen-Torvik LJ, Cushman M, Tsai MY, Zhang Y, Heckbert SR, Rosamond WD, Folsom AR (2007) The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study. Thromb Res 121:1–7. doi:10.1016/j.thromres.2007.02.008 PubMedCrossRef

43.

Carter AM, Catto AJ, Kohler HP, Ariens RA, Strickland MH, Grant PJ (2000) Alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 96:1177–1179PubMed

44.

Hooper WC, Lally C, Austin H et al (1999) The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. Chest 116:880–886. doi:10.1378/chest.116.4.880 PubMedCrossRef

45.

Dilley A, Austin H, Hooper WC et al (1998) Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 132:452–455. doi:10.1016/S0022-2143(98)90121-4 PubMedCrossRef

46.

Rahimy MC, Krishnamoorthy R, Ahouignan G, Laffan M, Vulliamy T (1998) The 20210A allele of prothrombin is not found among sickle cell disease patients from West Africa. Thromb Haemost 79:444PubMed

47.

Hooper WC, Roberts S, Dowling N, Austin H, Lally C, Whitsett C (2006) The prevalence of the prothrombin gene variant C20209T in African-Americans and Caucasians and lack of association with venous thromboembolism. Thromb Res 118:767–768. doi:10.1016/j.thromres.2005.12.001 PubMedCrossRef

48.

Dowling NF, Austin H, Dilley A, Whitsett C, Evatt BL, Hooper WC (2003) The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE study. J Thromb Haemost 1:80–87. doi:10.1046/j.1538-7836.2003.00031.x PubMedCrossRef

49.

Warshawsky I, Hren C, Sercia L et al (2002) Detection of a novel point mutation of the prothrombin gene at position 20209. Diagn Mol Pathol 11:152–156. doi:10.1097/00019606-200209000-00005 PubMedCrossRef

50.

Kearon C (2001) Epidemiology of venous thromboembolism. Semin Vasc Med 1:7–26. doi:10.1055/s-2001-14668 PubMedCrossRef

51.

Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet 346:1133–1134. doi:10.1016/S0140-6736(95)91803-5 PubMedCrossRef

52.

Svensson PJ, Zoller B, Mattiasson I, Dahlback B (1997) The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 241:379–385. doi:10.1046/j.1365-2796.1997.124140000.x PubMedCrossRef

53.

Tosetto A, Missiaglia E, Gatto E, Rodeghiero F (1997) The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza thrombophilia and atherosclerosis. Thromb Haemost 78:859–863PubMed

54.

Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504–1508PubMed

55.

Mikovic D, Rakicevic LJ, Kovac M, Radojkovic D (2000) Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance. Thromb Haemost 84:723–724PubMed

56.

Djordjevic V, Rakicevic LJ, Mikovic D et al (2004) Prevalence of factor V Leiden, factor V Cambridge, factor II G20210A and methylenetetrahydrofolate reductase C677T mutations in healthy and thrombophilic Serbian populations. Acta Haematol 112:227–229. doi:10.1159/000081280 PubMedCrossRef

57.

Pecheniuk NM, Marsh NA, Walsh TP, Dale JL (1997) Use of first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors. Blood Coagul Fibrinolysis 8:491–495. doi:10.1097/00001721-199711000-00002 PubMedCrossRef

58.

Dzimiri N, Meyer B (1996) World distribution of factor V Leiden. Lancet 347:481–482. doi:10.1016/S0140-6736(96)90064-1 PubMedCrossRef

59.

Poort RS, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMed

60.

Leroyer C, Mercier B, Oger E et al (1998) Prevalence of 20210A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 80:49–51PubMed

61.

Rosendaal FR, Doggen CJ, Zivelin A et al (1998) Geographic distribution of the 20210G to A prothrombin variant. Thromb Haemost 79:706–708PubMed

62.

Zalavras CG, Giotopoulou S, Dokou E et al (2003) Prevalence of the G20210A prothrombin gene mutation in Northwestern Greece and association with venous thromboembolism. Int Angiol 22:55–57PubMed

63.

Collaboration HomocysteineLoweringTrialists’ (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ 316:894–898

64.

Tucker KL, Olson B, Bakun P, Dallal GE, Selhub J, Rosenberg IH (2004) Breakfast cereal fortified with folic acid, vitamin B-6, and vitamin B-12 increases vitamin concentrations and reduces homocysteine concentrations: a randomized trial. Am J Clin Nutr 79:805–811PubMed

65.

Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH (1999) The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340:1449–1454. doi:10.1056/NEJM199905133401901 PubMedCrossRef

66.

Mezzano D, Leighton F, Martinez C et al (2001) Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors. Eur J Clin Nutr 55:444–451. doi:10.1038/sj.ejcn.1601202 PubMedCrossRef

67.

Steffen LM, Folsom AR, Cushman M, Jacobs DR Jr, Rosamond WD (2007) Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the longitudinal investigation of thromboembolism etiology. Circulation 115:188–195. doi:10.1161/CIRCULATIONAHA.106.641688 PubMedCrossRef

68.

Bergqvist D (2005) Geographical aspects of postoperative venous thromboembolism. J Thromb Haemost 3:26–27. doi:10.1111/j.1538-7836.2004.01098.x PubMedCrossRef

69.

Ho CH, Chwang LC, Hwang BH (1995) The influence of high fat diet on the fibrinolytic activity. Thromb Res 77:201–208. doi:10.1016/0049-3848(95)91607-M PubMedCrossRef

70.

Hammerschmidt DE (1980) Szechwan purpura. N Engl J Med 302:1191–1193PubMed

71.

Okuyama T, Shibata S, Hoson M (1986) Effect of oriental plant drugs on human platelet aggregation: III. Effect of Chinese drug “Xiebai” on human platelet aggregation. Planta Med 3:171–175. doi:10.1055/s-2007-969113 PubMedCrossRef

72.

Pomp ER, Rosendaal FR, Doggen CJ (2008) Alcohol consumption is associated with a decreased risk of venous thrombosis. Thromb Haemost 99:59–63PubMed

73.

Jick H, Derby LE, Wald Myers M, Vasilakis C, Newton KM (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981–983. doi:10.1016/S0140-6736(96)07114-0 PubMedCrossRef

74.

Goldhaber SZ, Grodstein F, Stampfer MJ et al (1997) A prospective study of risk factors for pulmonary embolism in women. JAMA 277:642–645. doi:10.1001/jama.277.8.642 PubMedCrossRef

75.

Eichinger S, Hron G, Bialonczyk C et al (2008) Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 168:1678–1683. doi:10.1001/archinte.168.15.1678 PubMedCrossRef

76.

Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P (2006) Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 367:1075–1079. doi:10.1016/S0140-6736(06)68474-2 PubMedCrossRef

77.

Samama MM (2000) An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160:3415–3420. doi:10.1001/archinte.160.22.3415 PubMedCrossRef

78.

Alikhan R, Cohen AT, Combe S et al (2004) Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 164:963–968. doi:10.1001/archinte.164.9.963 PubMedCrossRef

79.

Alikhan R, Spyropoulos AC (2008) Epidemiology of venous thromboembolism in cardiorespiratory and infectious disease. Am J Med 121:935–942. doi:10.1016/j.amjmed.2008.05.045 PubMedCrossRef

80.

Jansen JM, Lijfering WM, Sprenger HG, van der Meer J, van Pampus MG (2008) Venous thromboembolism in HIV-positive women during puerperium: a case series. Blood Coagul Fibrinolysis 19:95–97. doi:10.1097/MBC.0b013e3282f38c23 PubMedCrossRef

81.

Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC (2007) Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 110:908–912. doi:10.1182/blood-2006-11-057604 PubMedCrossRef

82.

Baccarelli A, Zanobetti A, Martinelli I et al (2007) Effects of exposure to air pollution on blood coagulation. J Thromb Haemost 5:252–260. doi:10.1111/j.1538-7836.2007.02300.x PubMedCrossRef

83.

Baccarelli A, Martinelli I, Zanobetti A et al (2008) Exposure to particulate air pollution and risk of deep vein thrombosis. Arch Intern Med 168:920–927. doi:10.1001/archinte.168.9.920 PubMedCrossRef

84.

Dalen JE (2008) Particulate air pollution exposure and risk of venous thromboembolism. Arch Intern Med 168:2497. doi:10.1001/archinternmed.2008.531 PubMedCrossRef

85.

Lippi G, Favaloro EJ, Franchini M, Guidi GC (2008) Air pollution and coagulation testing: a new source of biological variability? Thromb Res 123:50–54. doi:10.1016/j.thromres.2008.04.010 PubMedCrossRef

86.

Baccarelli A, Zanobetti A, Martinelli I et al (2007) Air pollution, smoking, and plasma homocysteine. Environ Health Perspect 115:176–181PubMedCrossRef

87.

Keenan CR, White RH (2005) Age as a risk factor for venous thromboembolism after major surgery. Curr Opin Pulm Med 11:398–402. doi:10.1097/01.mcp.0000174246.15386.69 PubMedCrossRef

88.

Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr (1994) The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154:861–866. doi:10.1001/archinte.154.8.861 PubMedCrossRef

89.

Nowak-Göttl U, Kosch A (2004) Factor VIII, D-dimer, and thromboembolism in children. N Engl J Med 351:1051–1053. doi:10.1056/NEJMp048150 PubMedCrossRef

90.

Kosch A, Koch HG, Heinecke A, Kurnik K, Heller C, Nowak-Göttl U, Childhood Thrombophilia Study Group (2004) Increased fasting total homocysteine plasma levels as a risk factor for thromboembolism in children. Thromb Haemost 91:308–314PubMed

91.

Bailey AL, Scantlebury DC, Smyth SS (2009) Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol 29:284–288. doi:10.1161/ATVBAHA.108.179788 PubMedCrossRef

92.

Zuern CS, Lindemann S, Gawaz M (2009) Platelet Function and Response to Aspirin: Gender-specific features and implications for female thrombotic risk and management. Semin Thromb Hemost, 35, (in press)

93.

Anderson FA Jr, Wheeler HB, Goldberg RJ et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 151:933–938. doi:10.1001/archinte.151.5.933 PubMedCrossRef

94.

Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T (1992) A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 232:155–160PubMedCrossRef

95.

Proctor MC, Wainess RM, Henke PK, Upchurch GR, Wakefield TW (2004) Venous thromboembolism: regional differences in the nationwide inpatient sample, 1993 to 2000. Vascular 12:374–380. doi:10.2310/6670.2004.00037 PubMedCrossRef

96.

Oger E (2000) Incidence of venous thromboembolism: a community-based study in western France. EPI-GETBP study group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83:657–660PubMed

97.

Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593. doi:10.1001/archinte.158.6.585 PubMedCrossRef

98.

Romero A, Alonso C, Rincón M et al (2005) Risk of venous thromboembolic disease in women a qualitative systematic review. Eur J Obstet Gynecol Reprod Biol 121:8–17. doi:10.1016/j.ejogrb.2004.11.023 PubMedCrossRef

99.

Moores L, Bilello KL, Murin S (2004) Sex and gender issues and venous thromboembolism. Clin Chest Med 25:281–297. doi:10.1016/j.ccm.2004.01.013 PubMedCrossRef

100.

Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ (2008) Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 6:632–637. doi:10.1111/j.1538-7836.2008.02921.x PubMedCrossRef

101.

Cushman M, Kuller LH, Prentice R, Women’sHealth Initiative Investigators et al (2004) Estrogen plus progestin and risk of venous thrombosis. JAMA 292:1573–1580. doi:10.1001/jama.292.13.1573 PubMedCrossRef

102.

Battaglioli T, Martinelli I (2007) Hormone therapy and thromboembolic disease. Curr Opin Hematol 14:488–493PubMed

103.

Kyrle P, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S (2004) The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350:2558–2563. doi:10.1056/NEJMoa032959 PubMedCrossRef

104.

Baglin T, Luddington R, Brown K, Baglin C (2004) High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2:2152–2155. doi:10.1111/j.1538-7836.2004.01050.x PubMedCrossRef

105.

McRae S, Tran H, Schulman S, Ginsberg J, Kearon C (2006) Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 368:371–378. doi:10.1016/S0140-6736(06)69110-1 PubMedCrossRef

106.

White RH, Dager WE, Zhou H, Murin S (2006) Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost 96:267–273PubMed

107.

Guidi GC, Lippi G (2009) Will “personalized medicine” need personalized laboratory approach? Clin Chim Acta 400:25–29. doi:10.1016/j.cca.2008.09.029 PubMedCrossRef

Title: The role of ethnicity, age and gender in venous thromboembolism
Authors: Martina Montagnana
Emmanuel J. Favaloro
Massimo Franchini
Gian Cesare Guidi
Giuseppe Lippi
Publication date: 01-05-2010
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 4/2010
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-009-0365-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction

Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease

Myocardial infarction due to late stent thrombosis following epileptic convulsive seizures

Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction

Fructose-1,6-bisphosphate inhibits in vitro and ex vivo platelet aggregation induced by ADP and ameliorates coagulation alterations in experimental sepsis in rats

Retinal vein occlusion: evaluation of “classic” and “emerging” risk factors and treatment

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials